Dishman Carbogen Amcis Passes USFDA Inspection with Flying Colors 5 days ago
Dishman Carbogen Amcis successfully completed a United States Food and Drug Administration (USFDA) inspection without any observations or issuance of Form 483. This outcome indicates no issues were identified during the inspection process, demonstrating the company's high-quality standards and compliance with international regulatory requirements. The successful inspection enhances the company's credibility, potentially boosting market confidence and opening opportunities for market expansion in the U.S. pharmaceutical sector.
Dishman Carbogen Amcis' Swiss Unit Secures Major Co-Investment Deal Jun 06, 2025
Dishman Carbogen Amcis Secures Milestone Drug Manufacturing License in Shanghai Apr 22, 2025
Dishman Carbogen Amcis Secures First Drug Manufacturing License in Shanghai, Boosting China Operations Apr 21, 2025
More news about Dishman Carbogen Amcis
11Apr 25
Dishman Carbogen Amcis Subsidiary Secures Drug Manufacturing License in Shanghai
Dishman Carbogen Amcis Limited's Shanghai-based subsidiary has obtained a drug manufacturing license from China's National Medical Products Administration (NMPA). This approval enables the company to manufacture pharmaceutical products at its Shanghai facility, potentially expanding its operations in the Chinese market. The license is expected to provide direct access to the Chinese pharmaceutical market, improve operational efficiency, and potentially drive revenue growth.
09Apr 25
Dishman Carbogen Amcis Subsidiary Secures Drug Manufacturing License in China, Expanding Asian Footprint
Dishman Carbogen Amcis Limited's wholly-owned subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., has received a drug manufacturing license from China's National Medical Products Administration (NMPA) on April 8, 2025. This license allows the company to manufacture pharmaceutical products in China, marking a significant step in its global expansion strategy and strengthening its presence in the Asian pharmaceutical market.
24Mar 25
Dishman Carbogen Amcis' Subsidiary Secures GMP Certification for Aseptic Drug Manufacturing in France
Dishman Carbogen Amcis Limited's subsidiary, Carbogen Amcis SAS, has obtained GMP certification for its new sterile drug product manufacturing facility in Saint-Beauzire, France. The certification follows a successful ANSM inspection and allows for manufacturing and release of clinical and commercial sterile drug products. The 60 million euro facility, opened in 2023, features advanced production lines and complies with latest EU GMP standards. This certification enhances the company's drug product manufacturing capabilities and strengthens its position in offering end-to-end pharmaceutical services.
Dishman Carbogen Amcis Limited's Board of Directors has approved the issuance of Non-Convertible Debentures (NCDs) worth up to ₹50 crore. The NCDs will be rated, listed, senior, secured, redeemable, and taxable, with a face value of ₹1,00,000 each. The debentures will have a 24-month tenure, a 10% annual coupon rate paid quarterly, and will be listed on the BSE's Wholesale Debt Market Segment. The NCDs will be secured by a first-ranking exclusive charge on a fixed deposit and an exclusive charge on identified freehold land, providing at least 1.25x security cover.
10Mar 25
Dishman Carbogen Amcis to Consider Fund Raising via Non-Convertible Debentures
Dishman Carbogen Amcis Limited has announced a board meeting on March 12 to discuss and potentially approve raising funds through non-convertible debentures (NCDs) via private placement. This move could strengthen the company's financial position without diluting existing shareholders' equity. The decision to explore NCDs suggests the company may be looking to optimize its capital structure or fund specific initiatives.
07Mar 25
Dishman Carbogen Amcis to Consider Fund Raising via NCDs in Upcoming Board Meeting
Dishman Carbogen Amcis Limited has scheduled a board meeting for March 12 to discuss and potentially approve the issuance of non-convertible debentures (NCDs) through private placement. This move indicates the company's strategy to raise funds, possibly for growth initiatives or capital structure management. The outcome of this meeting could significantly impact the company's financial strategy and market perception.